Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Gynecologic Oncology Highlights
Comprehensive Cancer Center Designation Trumps High Volume as Predictor for Outcomes in Ovarian Cancer
By
Charles Bankhead
Gynecologic Oncology Highlights
April 2015, Vol 6, No 3
Chicago, IL—The National Cancer Institute (NCI) designation of a comprehensive cancer center trumps high case volume as a predictor of outcomes in ovarian cancer, according to a single-region analysis.
Read Article
PARP Inhibitor Maintenance Too Pricey for Ovarian Cancer?
By
Charles Bankhead
Gynecologic Oncology Highlights
April 2015, Vol 6, No 3
Chicago, IL—Poly (ADP-ribose) polymerase (PARP) inhibitor maintenance therapy with olaparib (Lynparza) for relapsed, platinum-sensitive ovarian cancer would meet conventional standards of cost-effectiveness only if the drug price decreased by ?66%, according to a modeling study.
Read Article
Bevacizumab Prolongs Survival in Recurrent Platinum-Sensitive Ovarian Cancer
By
Alice Goodman
Gynecologic Oncology Highlights
April 2015, Vol 6, No 3
Chicago, IL—The addition of bevacizumab (Avastin) to standard chemotherapy extended survival in women with platinum-sensitive recurrent ovarian cancer compared with chemotherapy alone in the phase 3 randomized controlled GOG0213 trial. The results were presented at the 2015 Society of Gynecologic Oncology annual meeting.
Read Article
Immunotherapy Vaccine Prolongs Recurrence-Free Survival in Advanced Ovarian Cancer
By
Alice Goodman
Gynecologic Oncology Highlights
,
Immunotherapy
April 2015, Vol 6, No 3
Chicago, IL—Immunotherapy holds promise for the maintenance treatment of late-stage ovarian cancer, according to results of a phase 2 clinical trial. The vaccine, made from the patient’s own tumor cells, was able to prolong recurrence-free survival compared with standard of care.
Read Article
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma